Sanofi SA Q1 2024 Earnings Call Transcript - Thomson StreetEvents

Sanofi SA Q1 2024 Earnings Call Transcript

Sanofi SA Q1 2024 Earnings Call Transcript - Thomson StreetEvents
Sanofi SA Q1 2024 Earnings Call Transcript
Published Apr 25, 2024
23 pages (14936 words) — Published Apr 25, 2024
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of SASY.PA earnings conference call or presentation 25-Apr-24 12:30pm GMT

  
Brief Excerpt:

...Hello, everyone. It's Paul Hudson, the CEO of Sanofi. Welcome to the Q1 2024 conference call. You can find the slides of this call on the sanofi.com Investors page. I'd like to remind you that the information presented in this call contains forward-looking statements which is subject to substantial risks and uncertainties that may cause actual results to differ materially. I encourage you to read the disclaimer in our presentation. In addition, I refer you to our Form 20-F on file with the SEC (foreign language) for a description of these risk factors. I'm pleased to welcome our new CFO, Frantois to the presentation, and Frantois will be followed by Houman, our Head of R&D on the pipeline. For Q&A, we have Brian, Olivier, Thomas and Julie to cover the global business units and Roy our GC. (Operator Instructions). Let's turn to the business. We had an excellent start in 2024 with 7% sales growth, in line with our fast-moving portfolio transformation, our growth was driven by launches, including...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Sanofi SA
Ticker
SASY.PA
Time
12:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Jo Walton - UBS Investment Bank, Research Division - Analyst : Two quick questions then, please. On Altuviiio, I wonder, is there any evidence of moderate patients rather than severe patients beginning to try prophylaxis given that this is now an ability to get to a normal level of factor clotting, on Beyfortus, could you give us an idea of what the next countries would be? So you've obviously got potentially more demand than supply. What's the sort of order of countries that we should be thinking of as you roll out because you said you would be rolling out some more this year. If I can just finally say, is there any read across from the failure in frexelimab (inaudible) to any of the other indications or should we see that as completely isolated?

Table Of Contents

Sanofi SA Q4 2024 Earnings Call Transcript – 2025-01-30 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 30-Jan-25 2:00pm GMT

Sanofi SA at JPMorgan Healthcare Conference Transcript – 2025-01-14 – US$ 54.00 – Edited Transcript of SASY.PA presentation 14-Jan-25 5:45pm GMT

Sanofi SA Q3 2024 Earnings Call Transcript – 2024-10-25 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 25-Oct-24 12:00pm GMT

Sanofi SA Q2 2024 Earnings Call Transcript – 2024-07-25 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 25-Jul-24 12:30pm GMT

Sanofi SA at Goldman Sachs Global Healthcare Conference Transcript – 2024-06-11 – US$ 54.00 – Edited Transcript of SASY.PA presentation 11-Jun-24 12:00pm GMT

Sanofi SA at Leerink Partners Global Biopharma Conference Transcript – 2024-03-12 – US$ 54.00 – Edited Transcript of SASY.PA presentation 12-Mar-24 2:40pm GMT

Sanofi SA at TD Cowen Health Care Conference Transcript – 2024-03-04 – US$ 54.00 – Edited Transcript of SASY.PA presentation 4-Mar-24 5:50pm GMT

Sanofi SA Q4 2023 Earnings Call Transcript – 2024-02-01 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 1-Feb-24 1:30pm GMT

Sanofi SA R&D Day Transcript – 2023-12-07 – US$ 54.00 – Edited Transcript of SASY.PA corporate analyst meeting</ 7-Dec-23 1:30pm GMT

Sanofi SA Q3 2023 Earnings Call Transcript – 2023-10-27 – US$ 54.00 – Edited Transcript of SASY.PA earnings conference call or presentation 27-Oct-23 12:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Sanofi SA Q1 2024 Earnings Call Transcript" Apr 25, 2024. Alacra Store. May 21, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2024-Sanofi-SA-Earnings-Call-T15817008>
  
APA:
Thomson StreetEvents. (2024). Sanofi SA Q1 2024 Earnings Call Transcript Apr 25, 2024. New York, NY: Alacra Store. Retrieved May 21, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q1-2024-Sanofi-SA-Earnings-Call-T15817008>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.